A bankruptcy court this week approved the $305 million sale of genetics testing firm 23andMe to a nonprofit organization led by the company's former CEO Anne Wojcicki, the company announced. The ...

We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. Regeneron Pharmaceuticals, ...

After the company filed for bankruptcy in March, this week, the sale of 23andMe was completed after previously being approved by a judge.

That means Wojcicki’s nonprofit TTAM Research Institute will purchase “substantially all” of San Francisco-based 23andMe’s assets for $305 million. The transaction — which arrives more than three ...

After a couple of months of non-stop litigation, counsel for the debtor at Paul, Weiss and for the acquirer—a newly formed ...

Our previous report on the Chapter 11 case of 23andMe discussed the Sale Order entered by the Bankruptcy Court on June 27, ...

Me’s privacy ombudsman secured court approval to retain WilmerHale in the DNA testing company’s Chapter 11 case despite an ...

The largest genetic analysis of stuttering has demonstrated a clear genetic basis for the speech disorder, highlighting ...

To qualify for a cybersecurity-related claim, one must be a 23andMe customer between May 1, 2023, and Oct. 1, 2023; have ...

Biotech company 23andMe is filing for bankruptcy, prompting concerns over what will happen to its troves of genetic data. In a statement, the company said it is looking to sell “substantially ...

23andMe bankruptcy: Here's how to delete your data Chairman of the board said Sunday that the company has determined that a court-supervised sale was “the best path forward to maximize the value ...

A bankruptcy judge approved the sale of 23andMe's assets and business operations to a nonprofit led by 23andMe’s co-founder and former chief executive, Anne Wojcicki.